No Data
Kim Dawei: First Quarter Report 2025
Xiamen Kingdomway Group (002626.SZ): In the first quarter, the net income was 0.122 billion yuan, a year-on-year increase of 71.97%.
On April 28, Gelonghui reported that Xiamen Kingdomway Group (002626.SZ) released its first quarterly report for 2025, achieving revenue of 0.827 billion yuan, a year-on-year increase of 11.31%; net income attributable to shareholders of the listed company was 0.122 billion yuan, a year-on-year increase of 71.97%; net income attributable to shareholders of the listed company deducting non-recurring gains and losses was 0.119 billion yuan, a year-on-year increase of 70.03%; and EPS was 0.2 yuan.
The Three-year Shareholder Returns and Company Earnings Persist Lower as Xiamen Kingdomway Group (SZSE:002626) Stock Falls a Further 4.0% in Past Week
Kim Dawei: 2024 Annual Report Summary
Kim Dawei: 2024 Annual Report
The price increase of Vitamins helped Xiamen Kingdomway Group achieve a 24% increase in net profit last year, while the gross profit margin of the core product coenzyme Q10 continued to be under pressure.|Interpretations
① Xiamen Kingdomway Group had a poor start but ended strong last year, meeting Brokerage expectations; ② The price increase of VA was the main reason for the performance growth, but prices have dropped to low levels this year; ③ Core product coenzyme Q10 has seen strong production and sales but the gross profit continues to decline.
